Regeneron Pharmaceuticals, Inc. (REGN) 10-K 2026: AI Summary

Summary

Full summary

The Print

Regeneron's FY2025 total revenues rose 1.0% to $14,342.9M while net income increased 2.1% to $4,504.9M and diluted EPS reached $41.48, as a $1,352.6M increase in Sanofi collaboration revenue offset a $1,320.1M decline in total net product sales.

Total revenues increased $140.9M to $14,342.9M in 2025 from $14,202.0M in 2024. The increase reflected a $1,352.6M rise in Sanofi collaboration revenue to $5,884.0M, which the filing states was driven by higher profits primarily associated with an increase in Dupixent sales, and a $187.6M increase in other revenue to $702.6M, partly offset by a $1,320.1M decline in total net product sales to $6,309.1M. Within net product sales, EYLEA - U.S. declined $2,019.3M to $2,747.8M, which the filing attributes to lower sales volumes as a result of continued competitive pressures, loss in market share to compounded bevacizumab due to patient affordability constraints, and the continued transition of patients to EYLEA HD, and a lower net selling price; EYLEA HD - U.S. rose $435.8M to $1,636.9M due to higher sales volumes, partly offset by a lower net selling price. Income from operations declined $412.8M to $3,577.9M as total operating expenses increased $553.7M to $10,765.0M.

Total revenues of $14,342.9M (up 1.0% YoY) were driven by Sanofi collaboration revenue of $5,884.0M (up $1,352.6M), which management attributes to higher profits primarily associated with an increase in Dupixent sales.
Total net product sales fell to $6,309.1M (down $1,320.1M), as EYLEA - U.S. net product sales declined $2,019.3M to $2,747.8M, partly offset by EYLEA HD - U.S. net product sales of $1,636.9M (up $435.8M).
Income from operations declined to $3,577.9M from $3,990.7M, as total operating expenses rose $553.7M to $10,765.0M, including a $718.2M increase in research and development expenses to $5,850.2M.
Net income of $4,504.9M and diluted EPS of $41.48 benefited from total other income (expense) of $1,652.8M, which included $946.1M of gains on marketable and other securities, net.

Results That Matter

Total revenues
Current period
$14.3B
Prior period
$14.2B
Change
+1.0%
The increase reflected a $1,352.6M rise in Sanofi collaboration revenue to $5,884.0M, which the filing states was driven by higher profits primarily associated with an increase in Dupixent sales, partly offset by a $1,320.1M decline in total net product sales to $6,309.1M.
Income from operations
Current period
$3.6B
Prior period
$4.0B
Change
−10.3%
Total operating expenses increased $553.7M to $10,765.0M, including a $718.2M increase in research and development expenses to $5,850.2M, partly offset by a $254.4M decrease in selling, general, and administrative expenses to $2,700.0M.
Net income
Current period
$4.5B
Prior period
$4.4B
Change
+2.1%
Net income increased despite the decline in income from operations, as total other income (expense) rose to $1,652.8M from $789.2M, including $946.1M of gains on marketable and other securities, net, and $716.8M of interest income; income tax expense increased to $725.8M from $367.3M.
Net income per share - diluted
Current period
$41.5
Prior period
$38.3
Change
—
Diluted EPS grew faster than net income as weighted average shares outstanding - diluted declined to 108.6M from 115.1M.
Net income per share - basic
Current period
$43.1
Prior period
$40.9
Change
—
Basic EPS is computed on weighted average shares outstanding - basic of 104.6M in 2025 versus 107.9M in 2024.

Financial highlights: current period, prior period, change, and investor takeaway per metric
Metric	Current Period	Prior Period	Change	Investor Takeaway
Total revenues	$14.3B	$14.2B	+1.0%	The increase reflected a $1,352.6M rise in Sanofi collaboration revenue to $5,884.0M, which the filing states was driven by higher profits primarily associated with an increase in Dupixent sales, partly offset by a $1,320.1M decline in total net product sales to $6,309.1M.
Income from operations	$3.6B	$4.0B	−10.3%	Total operating expenses increased $553.7M to $10,765.0M, including a $718.2M increase in research and development expenses to $5,850.2M, partly offset by a $254.4M decrease in selling, general, and administrative expenses to $2,700.0M.
Net income	$4.5B	$4.4B	+2.1%	Net income increased despite the decline in income from operations, as total other income (expense) rose to $1,652.8M from $789.2M, including $946.1M of gains on marketable and other securities, net, and $716.8M of interest income; income tax expense increased to $725.8M from $367.3M.
Net income per share - diluted	$41.5	$38.3	—	Diluted EPS grew faster than net income as weighted average shares outstanding - diluted declined to 108.6M from 115.1M.
Net income per share - basic	$43.1	$40.9	—	Basic EPS is computed on weighted average shares outstanding - basic of 104.6M in 2025 versus 107.9M in 2024.

Earnings Quality & Cash Conversion

Income from operations of $3,577.9M included a $155.0M charge in research and development expenses related to an FDA Rare Pediatric Disease Priority Review Voucher, which the filing states was previously capitalized as an intangible asset. Total other income (expense) of $1,652.8M included $946.1M of gains on marketable and other securities, net, and $716.8M of interest income, and income tax expense of $725.8M included a $44.5M charge recognized in the third quarter of 2025 related to the re-measurement of U.S. net deferred tax assets as a result of the OBBBA being signed into law. The filing does not define an adjusted or ex-item earnings total.

Red flag

Total net product sales declined $1,320.1M to $6,309.1M while total revenues rose only $140.9M, with the increase concentrated in collaboration revenue rather than product sales.

Red flag

Income from operations declined $412.8M to $3,577.9M while net income rose $92.3M, with the difference attributable to a $863.6M increase in total other income (expense) to $1,652.8M.

Value Drivers & Capital Allocation

Capital expenditures $898.4M (prior $755.9M) (selected cash-flow amount, not necessarily total capital investment).

Return on equity was 14.4% (prior 15.0%) (period net income / period-end equity, not annualized); return on assets 11.1% (prior 11.7%) (period net income / period-end assets, not annualized).

Forward Signals

cautious

The filing provides no revenue, earnings, or EPS guidance. It states expected capital expenditures of $1.100 billion to $1.300 billion in 2026, including in connection with the continued expansion of facilities in Tarrytown, New York and developing the property in Saratoga Springs, New York, and states that it expects continued significant capital expenditures over the next several years related to these expansion projects.

Known trends

EYLEA net product sales have been, and are likely to continue to be, negatively impacted by increased competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.
Following the expiration of the U.S. regulatory exclusivity period for EYLEA in May 2024, several biosimilar versions of EYLEA have been approved by the FDA, and one such product has launched in the United States.
If independent not-for-profit patient assistance funds that provide copay assistance are unable to support eligible patients, this will likely have a continued negative impact on patient affordability resulting in lower utilization of higher-cost anti-VEGF agents.

Subsequent events

In January 2026, our board of directors declared a cash dividend of $0.94 per share on our Common Stock and Class A Stock, payable on March 5, 2026 to shareholders of record as of February 20, 2026.

“We expect to incur capital expenditures of $1.100 billion to $1.300 billion in 2026, including in connection with the continued expansion of our facilities in Tarrytown, New York and developing our property in Saratoga Springs, New York for production support activities and additional manufacturing capacity.”
— Regeneron Pharmaceuticals, Inc.

“We have also recently committed to matching donations for up to a total of $200 million during 2026.”
— Regeneron Pharmaceuticals, Inc.

Risks

5 source-verified filing excerpts. Selected excerpts are not a complete risk inventory.

Filing excerpt 1

EvidenceFor the years ended December 31, 2025 and 2024, our aggregate EYLEA HD and EYLEA net product sales in the United States represented 31% and 42% of our total revenues, respectively.

Filing excerpt 2

EvidenceFor the years ended December 31, 2025 and 2024, Sanofi collaboration revenue (most of which is attributable to our share of profits from the commercialization of Dupixent) represented 41% and 32% of our total revenues, respectively.

Filing excerpt 3

EvidenceEYLEA and/or EYLEA HD net product sales recorded by us are likely to continue to be negatively impacted by biosimilar competition in the United States, including competition from additional biosimilar versions of EYLEA expected to launch in the United States in the second half of 2026, which may have a material adverse impact on our results of operations.

Filing excerpt 4

EvidenceLiabilities for unrecognized tax benefits totaled $1.578 billion as of December 31, 2025. Due to their nature, there is a high degree of uncertainty regarding the period and amounts of potential future cash settlement with tax authorities.

Filing excerpt 5

EvidenceAs of December 31, 2025, our contingent reimbursement obligation to Sanofi in connection with the development balance was approximately $595 million and our contingent reimbursement obligation to Bayer was approximately $296 million.

Balance Sheet & Liquidity

Leverage: Identified debt as of 2025-12-31: reported debt balance of unestablished maturity scope of $2.0B. The concept behind this balance does not establish which maturities it covers. Total debt, net debt and debt-to-equity are therefore not stated.

Liquidity: Cash and cash equivalents of $3,118.1M plus current marketable securities of $5,487.1M and noncurrent marketable securities of $10,260.6M totaled $18,865.8M of financial assets as of December 31, 2025, up $953.2M from $17,912.6M. Borrowing availability of $750.0M existed under a revolving credit facility, with no borrowings outstanding as of December 31, 2025.

Cash flow: Cash flow — operating $5.0B, investing $-629.1M, financing $-3.7B.

Working capital: Current assets $18.0B vs. current liabilities $4.4B (current ratio 4.13x). Prior reported balance sheet as of 2024-12-31: $18.7B vs. $3.9B (4.73x).

Maturities & covenants

The Credit Agreement provides for a $750.0 million senior unsecured five-year revolving credit facility and contains operating covenants and a maximum total leverage ratio financial covenant; the Company was in compliance with all covenants as of December 31, 2025.
The Tarrytown, New York lease financing of $720.0 million matures when the term of the Lease expires in March 2027, at which time all amounts outstanding thereunder will become payable in full.

Notable Footnotes

Item	Impact
Uncertain tax positions	Reserves for uncertain tax positions were $1,577.9 million as of December 31, 2025, and were identified by the auditor as a critical audit matter.
Sales-related deductions	The balance of provisions for rebates, chargebacks, and discounts; distribution-related fees; and other sales-related deductions rose to $870.8 million as of December 31, 2025 from $760.4 million as of December 31, 2024, with 2025 provisions of $3,292.5 million and credits/payments of $3,182.1 million.
Stock-based compensation	Operating expenses in 2025 included stock-based compensation expense of $993.7 million, and unrecognized stock-based compensation expense related to unvested stock options and unvested restricted stock was $385.8 million and $1.493 billion, respectively, as of December 31, 2025.
Libtayo contingent consideration	Payments for intangible assets in 2025, 2024, and 2023 included $160.3 million, $125.7 million, and $207.8 million, respectively, for contingent consideration paid to Sanofi in connection with the acquisition of worldwide rights to Libtayo in 2022.

Ask REGN’s 10-K anything

Get plain-English answers, each cited to the exact filing text. Try a starter question:

AI-generated. Informational only, not investment advice. May be incomplete or contain errors. The authoritative source is always the original SEC filing.